1
|
Lenalidomide after stem-cell transplantation for multiple myeloma.
|
N Engl J Med
|
2012
|
6.24
|
2
|
The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications.
|
Blood
|
2002
|
3.73
|
3
|
Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341.
|
Blood
|
2002
|
3.62
|
4
|
Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications.
|
Oncogene
|
2002
|
2.66
|
5
|
Molecular sequelae of histone deacetylase inhibition in human malignant B cells.
|
Blood
|
2003
|
1.92
|
6
|
Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib.
|
Blood
|
2012
|
1.91
|
7
|
Autologous and allogeneic stem cell transplantations for poor-risk chronic lymphocytic leukemia.
|
Blood
|
2005
|
1.89
|
8
|
New drugs for myeloma.
|
Oncologist
|
2007
|
1.84
|
9
|
Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: clinical implications.
|
Cancer Res
|
2005
|
1.84
|
10
|
Weekly bortezomib in combination with temsirolimus in relapsed or relapsed and refractory multiple myeloma: a multicentre, phase 1/2, open-label, dose-escalation study.
|
Lancet Oncol
|
2011
|
1.66
|
11
|
Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study.
|
Blood
|
2006
|
1.63
|
12
|
Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment.
|
Cancer Res
|
2006
|
1.62
|
13
|
Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235.
|
Cancer Res
|
2009
|
1.54
|
14
|
NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma.
|
Blood
|
2003
|
1.53
|
15
|
Thalidomide for patients with relapsed multiple myeloma after high-dose chemotherapy and stem cell transplantation: results of an open-label multicenter phase 2 study of efficacy, toxicity, and biological activity.
|
Mayo Clin Proc
|
2004
|
1.43
|
16
|
Human anti-CD40 antagonist antibody triggers significant antitumor activity against human multiple myeloma.
|
Cancer Res
|
2005
|
1.42
|
17
|
Bortezomib in the front-line treatment of multiple myeloma.
|
Expert Rev Anticancer Ther
|
2008
|
1.36
|
18
|
Graft-versus-tumor response in patients with multiple myeloma is associated with antibody response to BCMA, a plasma-cell membrane receptor.
|
Blood
|
2005
|
1.24
|
19
|
Targeting p38 MAPK inhibits multiple myeloma cell growth in the bone marrow milieu.
|
Blood
|
2002
|
1.15
|
20
|
Perifosine plus bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma previously treated with bortezomib: results of a multicenter phase I/II trial.
|
J Clin Oncol
|
2011
|
1.14
|
21
|
The bortezomib/proteasome inhibitor PS-341 and triterpenoid CDDO-Im induce synergistic anti-multiple myeloma (MM) activity and overcome bortezomib resistance.
|
Blood
|
2003
|
1.12
|
22
|
Novel therapy with 2-methoxyestradiol for the treatment of relapsed and plateau phase multiple myeloma.
|
Clin Cancer Res
|
2007
|
1.04
|
23
|
Immunologic effects of prophylactic donor lymphocyte infusion after allogeneic marrow transplantation for multiple myeloma.
|
Blood
|
2002
|
1.02
|
24
|
The treatment of relapsed and refractory multiple myeloma.
|
Hematology Am Soc Hematol Educ Program
|
2007
|
1.02
|
25
|
Targeting mitochondria to overcome conventional and bortezomib/proteasome inhibitor PS-341 resistance in multiple myeloma (MM) cells.
|
Blood
|
2004
|
1.01
|
26
|
Emerging drugs in multiple myeloma.
|
Expert Opin Emerg Drugs
|
2007
|
0.95
|
27
|
CD20-Directed Antibody-Mediated Immunotherapy Induces Responses and Facilitates Hematologic Recovery in Patients With Waldenstrom's Macroglobulinemia.
|
J Immunother (1991)
|
2001
|
0.94
|
28
|
New treatments for multiple myeloma.
|
Oncology (Williston Park)
|
2005
|
0.94
|
29
|
Tumor Cell Expression of CD59 Is Associated With Resistance to CD20 Serotherapy in Patients With B-Cell Malignancies.
|
J Immunother (1991)
|
2001
|
0.91
|
30
|
Expansion of tumor-specific CD8+ T cell clones in patients with relapsed myeloma after donor lymphocyte infusion.
|
Cancer Res
|
2003
|
0.90
|
31
|
Novel therapeutic avenues in myeloma: changing the treatment paradigm.
|
Oncology (Williston Park)
|
2007
|
0.89
|
32
|
Lenalidomide in multiple myeloma: an evidence-based review of its role in therapy.
|
Core Evid
|
2010
|
0.89
|
33
|
Molecular and cellular effects of multi-targeted cyclin-dependent kinase inhibition in myeloma: biological and clinical implications.
|
Br J Haematol
|
2011
|
0.85
|
34
|
Managing multiple myeloma: the emerging role of novel therapies and adapting combination treatment for higher risk settings.
|
Br J Haematol
|
2011
|
0.82
|
35
|
Painful tongue ulcerations in patients with bisphosphonate-associated osteonecrosis of the jaws.
|
Oral Surg Oral Med Oral Pathol Oral Radiol Endod
|
2008
|
0.81
|
36
|
Expression of serotherapy target antigens in Waldenstrom's macroglobulinemia: therapeutic applications and considerations.
|
Semin Oncol
|
2003
|
0.81
|
37
|
Flowing cells through pulsed electric fields efficiently purges stem cell preparations of contaminating myeloma cells while preserving stem cell function.
|
Blood
|
2004
|
0.81
|
38
|
Engraftment of autologous and allogeneic marrow HPCs after myeloablative therapy.
|
Transfusion
|
2004
|
0.80
|
39
|
Emerging trends in the clinical use of bortezomib in multiple myeloma.
|
Clin Lymphoma Myeloma
|
2005
|
0.78
|
40
|
Lenalidomide desensitization for delayed hypersensitivity reactions in 5 patients with multiple myeloma.
|
Br J Haematol
|
2014
|
0.78
|
41
|
The treatment of multiple myeloma patients not eligible for asct.
|
Mediterr J Hematol Infect Dis
|
2010
|
0.78
|
42
|
Bortezomib in the management of multiple myeloma.
|
Cancer Manag Res
|
2009
|
0.77
|
43
|
Endothelial stress products and coagulation markers in patients with multiple myeloma treated with lenalidomide plus dexamethasone: an observational study.
|
Br J Haematol
|
2012
|
0.76
|
44
|
Conflicts of interest, authorship, and disclosures in industry-related scientific publications.
|
Mayo Clin Proc
|
2010
|
0.75
|